Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study.
Carlotta PalumboAlessandro AntonelliLuca TriggianiAlberto Dalla VoltaFilippo MaffezzoniStefania ZamboniPaolo BorghettiLuca RinaudoFrancesca ValcamonicoRoberto MaroldiStefano Maria MagriniClaudio SimeoneAlfredo Berrutinull nullPublished in: Prostate cancer and prostatic diseases (2021)
The BLADE study prospectively evaluated changes in body composition after LHRH-antagonist. LHRH-antagonist therapy is associated to an increased risk of obesity and diabetes, but lean body mass and serum lipids are not affected. This may represent an additional evidence supporting the reduced cardiovascular risk associated with LHRH-antagonist. The role of FSH in influencing sarcopenic obesity in PCa after androgen deprivation deserves to be further explored.
Keyphrases
- body composition
- bone mineral density
- resistance training
- prostate cancer
- type diabetes
- insulin resistance
- metabolic syndrome
- end stage renal disease
- weight loss
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cardiovascular disease
- high fat diet induced
- radical prostatectomy
- peritoneal dialysis
- prognostic factors
- glycemic control
- postmenopausal women
- body mass index
- cell therapy
- high intensity
- smoking cessation
- combination therapy